A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus.

Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate Safety and Efficacy of PHX1149T as Monotherapy in Subjects With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Dutogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PROT301
  • Sponsors Phenomix Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Apr 2010 Secondary endpoint 'Fasting glucose level' and "Postprandial glucose level' have been met in recipients of dutogliptin (400 mg/day) according to top-line results reported in a Phenomix Corporation media release.
    • 21 Apr 2010 Top-line results have been reported in a Phenomix Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top